凯梅拉治疗公司的董事卖掉了63万美元的股票, Kymera Therapeutics director sold $631k in stock as revenue dropped 60.8%.

凯梅拉治疗公司的董事Elena Ridloff在另一位董事分别出售了7,400股价值631,738美元. Kymera Therapeutics director Elena Ridloff sold 7,400 shares worth $631,738 on March 31, following a separate sale by another director. 生物制药公司报告收入大幅下降60.8%, 并没有达到分析师的预期. The biopharmaceutical company reported a steep 60.8% drop in revenue and missed analyst earnings expectations. 尽管内部活动,分析师保持"中等购买"评级的目标价格为118.90美元. Despite insider activity, analysts maintain a "Moderate Buy" rating with a target price of $118.90.